Analyst Price Targets — CRVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 11:14 am | Raghuram Selvaraju | H.C. Wainwright | $25.00 | $7.02 | TheFly | CervoMed upgraded to Buy from Neutral at H.C. Wainwright |
| October 17, 2025 10:25 am | — | Roth Capital | $20.00 | $7.60 | TheFly | CervoMed price target raised to $20 from $16 at Roth Capital |
| August 12, 2025 11:59 am | Boobalan Pachaiyappan | Roth Capital | $16.00 | $9.41 | TheFly | CervoMed price target lowered to $16 from $20 at Roth Capital |
| September 18, 2024 5:17 am | Danill Gataulin | Loop Capital Markets | $16.32 | $4.79 | StreetInsider | Chardan Capital Markets Starts CervoMed (CRVO) at Buy |
| September 18, 2024 5:05 am | Daniil Gataulin | Chardan Capital | $16.32 | $4.79 | TheFly | CervoMed initiated with a Buy at Chardan |
| April 8, 2024 7:06 am | Sumant Kulkarni | Canaccord Genuity | $19.29 | $6.08 | StreetInsider | CervoMed (CRVO) PT Raised to $65 at Canaccord Genuity |
Latest News for CRVO
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from…
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.8 per share a year ago.
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension To ensure that plasma drug concentrations associated with therapeutic activity are achieved,…
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRVO.
U.S. House Trading
No House trades found for CRVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.